Alpelisib + Alpelisib matching Placebo + Trastuzumab + Pertuzumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced HER2+Breast Cancer
Conditions
Advanced HER2+Breast Cancer
Trial Timeline
Jul 16, 2020 → Feb 26, 2027
NCT ID
NCT04208178About Alpelisib + Alpelisib matching Placebo + Trastuzumab + Pertuzumab
Alpelisib + Alpelisib matching Placebo + Trastuzumab + Pertuzumab is a phase 3 stage product being developed by Novartis for Advanced HER2+Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04208178. Target conditions include Advanced HER2+Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04208178 | Phase 3 | Active |
Competing Products
20 competing products in Advanced HER2+Breast Cancer